| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2010-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e1744f56a9ff93dae60eca4064b24f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a4d7b76d854221991fc40b7a58f2494 |
| publicationDate |
2012-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-102341102-A |
| titleOfInvention |
Use of pyrimidinylaminobenzamide derivatives for the treatment of diseases mediated by kinases (ZAK) comprising leucine zipper and sterile alpha motifs |
| abstract |
The present invention relates to the use of pyrimidinylaminobenzamide derivatives of formula (I) or pharmaceutically acceptable salts thereof wherein the groups have the meanings defined herein in the preparation of pharmaceutical compositions for the treatment of diseases mediated by ZAK , relates to the use of pyrimidinylaminobenzamide derivatives of formula (I) or pharmaceutically acceptable salts thereof in the treatment of diseases mediated by ZAK, and to the treatment of warm, including human, suffering from diseases mediated by ZAK A method for a blood animal by administering an effective dose of a pyrimidinylaminobenzamide of formula (I) or a pharmaceutically acceptable salt thereof to said warm-blooded animal in need of such treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108117553-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108117553-A |
| priorityDate |
2009-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |